American biopharmaceutical company Veradermics has reported results from a Phase 3 trial of its investigational drug VDPHL01. The treatment could expand options for managing hair loss, but several important steps remain before it can be approved.
Hair loss has spawned a vast market for vitamins, serums, and shampoos. Many products promise to restore hair density, yet not all are supported by convincing scientific evidence.
Against this backdrop, Veradermics has attracted attention. In October 2026, the company announced positive results from a Phase 3 clinical trial of VDPHL01, an extended-release oral formulation of minoxidil.
The findings are promising. However, it is important to understand what the trial actually demonstrated, how safe the drug appears to be, and when it might become available to patients.
What Has Veradermics Developed?
VDPHL01 contains minoxidil, a compound that has been used in medicine for several decades. Topical formulations are used to treat certain types of hair loss, while low-dose oral minoxidil is also prescribed in dermatological practice, including off-label for hair loss.
Veradermics’ approach focuses on an extended-release delivery system designed to control how the active ingredient is released. The company is investigating whether this formulation can provide effective treatment with an acceptable safety profile.
In other words, this is not the discovery of a new hair-growth compound, but the development of a new formulation of an existing medication.
Oral minoxidil is not a universal treatment for every type of hair loss. Medical assessment is essential because thinning can have many different causes, each requiring a different approach.
What Did the Phase 3 Trial Show?
On October 19, 2026, Veradermics reported results from Study 304, which enrolled 536 men with mild to moderate androgenetic alopecia. This common form of hereditary hair loss causes hair follicles to gradually shrink, producing finer hair and reduced density.
Participants were randomly assigned to one of three groups: one took the drug once daily, another twice daily, and the third received a placebo. The trial was double-blind and placebo-controlled.
After six months, the average changes in hair count in the target area were as follows:
Once-daily treatment: an increase of 28.6 hairs per square centimetre.
Twice-daily treatment: an increase of 36.4 hairs per square centimetre.
Placebo: an increase of 6.6 hairs per square centimetre.
The differences between the treatment groups and the placebo group were statistically significant.
Participants were also asked to assess changes in the appearance of their hair. Improvement or significant improvement was reported by 55.7% of men taking the drug once daily and 68.7% of those taking it twice daily. In the placebo group, 15% reported improvement.
These findings indicate that the drug had a measurable effect under the conditions of the trial. However, an increase in hair count within a defined area does not mean every patient will regain their original hair density. Individual results may vary.
A fuller assessment will also require detailed trial data and continued follow-up of participants.
How Safe Is the Drug?
In its report on Study 304, the company did not identify serious treatment-related adverse events or cardiac adverse events of special interest. More than 1,000 men participated in the company’s two registrational studies.
Nevertheless, some side effects were observed. Peripheral oedema, or swelling caused by fluid accumulation, occurred in 2.8% of participants taking the drug once daily and 4.5% of those taking it twice daily. The rate in the placebo group was 0.6%.
Hypertrichosis, or excessive hair growth in unwanted areas, was reported in 2.2% of the once-daily group, 9% of the twice-daily group, and 0% of the placebo group.
These findings do not establish that the drug is unsafe, but they highlight why treatment must be assessed in terms of both effectiveness and potential adverse effects.
Minoxidil is a vasodilator, meaning it widens blood vessels. When taken orally, it can affect blood pressure and may cause a rapid heartbeat or fluid retention. Before prescribing it, a clinician must assess the patient’s health and potential risks.
Six-month results also cannot provide a complete picture of safety over years of use. Rare complications and certain long-term effects may only become apparent through more prolonged monitoring.
When Could the Drug Reach Pharmacies?
Positive Phase 3 results represent an important milestone in drug development, but they do not automatically lead to marketing approval.
Regulatory authorities must assess the complete evidence on efficacy, safety, dosing, and manufacturing quality. Only after this review can a drug be authorised for use.
As of October 29, 2026, VDPHL01 has not received approval from the US Food and Drug Administration (FDA).
There is therefore no confirmed date for its arrival in pharmacies. The timeline will depend on the company’s next steps and regulatory decisions.
What Do We Know About Its Effectiveness in Women?
Veradermics is also studying VDPHL01 as a potential treatment for androgenetic alopecia in women.
In July 2026, the company reported results from a Phase 2 study. It was an open-label trial, meaning participants knew they were receiving the investigational drug, and there was no separate placebo group.
Depending on the dosing regimen, average hair counts in the target area increased by 22.7 and 23.3 hairs per square centimetre. Improved hair coverage was reported by 88.9% and 90% of participants, respectively.
However, without a control group, it is harder to determine how much of the improvement was directly attributable to the drug. These results cannot be compared directly with those of a large, placebo-controlled trial in men.
In August, the company announced that recruitment had been completed for Phase 3 Study 306, which was designed to enrol 556 women. Initial results were expected in the first half of 2027.
The preliminary findings support further investigation of VDPHL01 in women, but definitive conclusions about its effectiveness must wait for stronger evidence.
What Hair-Loss Treatments Are Available Now?
While VDPHL01 remains under investigation, several established treatment options are already available. The most appropriate choice depends on the diagnosis, sex, age, and overall health of the patient.
Topical minoxidil is one of the best-studied treatments for androgenetic alopecia. It can stimulate hair growth and slow further thinning. Results are generally assessed after several months, and continued use is usually necessary to maintain the benefits.
Low-dose oral minoxidil is prescribed by some dermatologists off-label for hair loss. It is not suitable for everyone and requires an assessment of contraindications and cardiovascular risks.
Spironolactone may be used to treat androgenetic alopecia in some women. It is a prescription medication that requires medical supervision and is contraindicated during pregnancy.
Correcting nutritional deficiencies is important when hair loss is linked to iron deficiency or another confirmed problem. However, taking supplements without an identified deficiency does not guarantee improvement.
Vitamin and mineral supplements are not a universal solution. Excessive amounts of certain nutrients, including vitamin A and selenium, can themselves contribute to hair loss.
For significant or persistent thinning, a clinician may recommend a complete blood count, tests assessing iron status, and thyroid function tests. Additional investigations depend on the symptoms and suspected cause.
Conclusion:
The Phase 3 results for VDPHL01 in men are encouraging. The drug demonstrated a statistically significant advantage over placebo in increasing hair count, and some participants reported visible improvement.
However, important questions remain about long-term safety, individual responses, and the timing of potential regulatory approval. The findings in women are still preliminary and require confirmation in larger controlled trials.
VDPHL01 could become another treatment option for androgenetic alopecia, but it remains an investigational drug. There is still no universal pill guaranteed to restore hair regardless of the cause of hair loss.
Anyone experiencing noticeable hair thinning should first establish the underlying cause and then discuss treatments with proven effectiveness for their specific diagnosis with a qualified healthcare professional.
